Pendolino AL, Kwame I, Poirrier AL, et al. - Researchers conducted this pilot study to assess the impact of co-phenylcaine (lidocaine 5% and phenylephrine 0.5%) administered via nasal spray on 27 patients undergoing drug-induced sleep endoscopy (DISE) for sleep-disordered breathing disease and to assess whether the application of co-phenylcaine could or not significantly influence the grading outcome and thereby influence the patient’s treatment plan. The application of nasal spray did not influence the outcomes of DISE regardless of gender, AHI, BMI, tonsil grade, rhinitis presence, turbinate hypertrophy, nasal septal deviation or restriction of nasal peak inspiratory flow. The loudness of snoring was not substantially affected by co-phenylcaine. According to findings, the use of co-phenylcaine nasal spray during DISE was supported and the positive effects of the nasal spray do not affect the grading outcome. Importantly, the decongestant enhances nasal evaluation during DISE and potentially helps in the diagnosis of nasal obstruction, while the nasal anaesthetic component may be beneficial by decreasing nasal discomfort during DISE and thereby helping to lessen the total intravenous anaesthetic dose. However, to verify the outcomes, further research on a larger population are required.